Aardvark Therapeutics, Inc. (AARD) Q3 2025 10-Q Quarterly Report
Aardvark Therapeutics, Inc. (AARD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Aardvark Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Material weakness in internal control over financial reporting identified, may affect accurate or timely financial reporting and investor confidence
- • Material update: Net loss increased from $11.8M to $40.0M for nine months ended Sept 30, driven by higher R&D and G&A expenses
- • Regulatory risk: FDA regulatory approval for ARD-101 Phase 3 trial and NDA submission remain lengthy, unpredictable, with potential additional trial requirements
- • Operational risk: Reliance on third parties for clinical trials and manufacturing may delay development if contractual or regulatory standards not met
- • Financial risk: Cash, cash equivalents, and short-term investments $126.4M as of Sept 30, expected to fund operations into 2027 but may require earlier capital raise
Aardvark Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$0
Net Income
-$16M
▼ -13.6% QoQ
ROE
-13.3%
Total Assets
$133M
EPS (Diluted)
$-0.76
▼ -16.9% QoQ
Operating Cash Flow
-$16M
▼ -63.9% QoQ
Source: XBRL data from Aardvark Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Aardvark Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.